{"id":11581,"date":"2023-11-09T10:38:49","date_gmt":"2023-11-09T10:38:49","guid":{"rendered":"https:\/\/infundpros.com\/business\/astrazeneca-signs-deal-for-oral-weight-loss-drug-and-lifts-profit-outlook\/"},"modified":"2023-11-09T10:38:49","modified_gmt":"2023-11-09T10:38:49","slug":"astrazeneca-signs-deal-for-oral-weight-loss-drug-and-lifts-profit-outlook","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=11581","title":{"rendered":"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook"},"content":{"rendered":"<div>\n<p>Unlock the Editor\u2019s Digest for free<\/p>\n<p class=\"article__content-sign-up-topic-description\"><span>Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.<\/span><\/p>\n<p><iframe class=\"article__content-sign-up-iframe close\" scrolling=\"no\" id=\"signUpIframe\" data-prev-url=\"\/register\/in-article-sign-up?ft-content-uuid=c96bafc8-0ba9-4a24-9239-c5d5ee0d5051\"><\/iframe><\/div>\n<div id=\"article-body\">\n<p>AstraZeneca is to enter the race for a weight loss pill, as it raised its profit outlook on strong demand for its cancer drugs.<\/p>\n<p>The Anglo-Swedish drugmaker announced a licensing agreement for an oral medicine belonging to the same class as Novo Nordisk\u2019s blockbuster Wegovy drug, which treats conditions including diabetes and obesity that affect more than 1bn people globally.<\/p>\n<p>The company also reported a 6 per cent increase in revenues in the third quarter as demand for its oncology and rare disease drugs offset declining sales of Covid-19 vaccines.<\/p>\n<p>AstraZeneca is now expecting total revenue excluding Covid drugs to increase by a low-teens percentage, up from a previously guided low double-digit rise. Core earnings per share are forecast to rise by as much as a high double-digit percentage, up from a best-case scenario of a low double-digit rise. <\/p>\n<p>Shares in AstraZeneca rose 2.7 per cent on Thursday morning, <\/p>\n<p>AstraZeneca\u2019s agreement is with China\u2019s Eccogene and worth up to $2.01bn in total, with Eccogene receiving $185mn as an upfront payment to give exclusive global rights, excluding China, to the development and marketing of the drug. A further $1.83bn will be payable depending on milestones.<\/p>\n<p>Demand for the injectable Wegovy has pushed up shares in Novo Nordisk by almost 50 per cent in the year to date. And competition is heating up, with regulators on both sides of the Atlantic this week approving Eli Lilly\u2019s injectable diabetes medication for use as a weight loss treatment, making it the first direct rival to Wegovy.<\/p>\n<p>AstraZeneca\u2019s medicine would be in pill form, potentially giving the company a strong position in a booming market. The drugmaker said the molecule was in early clinical trials, but it had shown a clinical profile encouraging blood sugar and body weight reduction, as well as \u201cdesirable\u201d safety and tolerability data.<\/p>\n<p>Sharon Barr, executive vice-president for biopharmaceutical research and development at AstraZeneca, said she believed the drug \u201ccould offer alternatives to current injectable therapies\u201d.<\/p>\n<p>Excluding coronavirus products, third-quarter sales at AstraZeneca grew 13 per cent to $11.49bn, beating estimates and boosted by oncology and rare diseases, two of the company\u2019s key areas of focus. <\/p>\n<p>Pascal Soriot, chief executive, said the company \u201ccontinued its strong growth trajectory\u201d and that the decision to raise guidance was because of \u201cthe momentum in the year to date\u201d.<\/p>\n<p>In the third quarter, AstraZeneca oncology and cardiovascular drug sales grew 17 per cent and 16 per cent respectively, the company said on Thursday. But sales of its Covid vaccine and antibody treatment flatlined to zero, compared with $716mn in the same period in 2022.<\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.ft.com\/content\/c96bafc8-0ba9-4a24-9239-c5d5ee0d5051\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unlock the Editor\u2019s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":{"0":"post-11581","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AstraZeneca signs deal for oral weight loss drug and lifts profit outlook | inFundPros<\/title>\n<meta name=\"description\" content=\"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.AstraZeneca is to enter the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=11581\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook | inFundPros\" \/>\n<meta property=\"og:description\" content=\"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.AstraZeneca is to enter the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=11581\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-09T10:38:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-wall.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=11581#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=11581\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook\",\"datePublished\":\"2023-11-09T10:38:49+00:00\",\"dateModified\":\"2023-11-09T10:38:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=11581\"},\"wordCount\":466,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=11581#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=11581\",\"url\":\"https:\/\/infundpros.com\/?p=11581\",\"name\":\"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-11-09T10:38:49+00:00\",\"dateModified\":\"2023-11-09T10:38:49+00:00\",\"description\":\"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.AstraZeneca is to enter the\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=11581#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=11581\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=11581#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook | inFundPros","description":"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.AstraZeneca is to enter the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=11581","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook | inFundPros","og_description":"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.AstraZeneca is to enter the","og_url":"https:\/\/infundpros.com\/?p=11581","og_site_name":"inFundPros","article_published_time":"2023-11-09T10:38:49+00:00","og_image":[{"width":1920,"height":1200,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-wall.jpg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=11581#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=11581"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook","datePublished":"2023-11-09T10:38:49+00:00","dateModified":"2023-11-09T10:38:49+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=11581"},"wordCount":466,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=11581#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=11581","url":"https:\/\/infundpros.com\/?p=11581","name":"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-11-09T10:38:49+00:00","dateModified":"2023-11-09T10:38:49+00:00","description":"Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.AstraZeneca is to enter the","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=11581#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=11581"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=11581#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca signs deal for oral weight loss drug and lifts profit outlook"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11581"}],"version-history":[{"count":0,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11581\/revisions"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}